Unlocking the Value of Genetics with Real Data and Real ROI: A CancerIQ Webinar Series

WEBINAR RECORDINGS

Unlocking the Value of Genetics with Real Data and Real ROI: A CancerIQ Webinar Series

We know that cancer genetic risk assessment (GCRA) and a risk-based approach to cancer prevention and early detection are essential for clinical success, and even payers acknowledge the financial benefits. So why isn’t it happening at scale in provider organizations? Many genetics and high-risk programs lack the financial resources or staffing to deliver these services broadly. To help you make a strong business case to leadership in 2025, we’re offering a two-part webinar series that will highlight both the clinical and financial benefits of comprehensive GCRA programs.

PART 1 PART 2

PART 1

Real-World Data on Returns from Programs in the CancerIQ Network

Review trends in patient volumes, adherence rates to medical management recommendations, and how these drive downstream revenue
Hear real-world examples from CancerIQ’s network on how these programs lead to measurable returns
Leave with an ROI calculator to apply directly to your genetics program

Speaker:

Feyi Ayodele, CEO, CancerIQ

PART 2

Invitation to the VALUE Study – Quantifying Clinical and Financial Benefits

Hear from study leadership about the new multi-site VALUE Study, which aims to quantify the clinical and financial benefits of GCRA programs using real claims-verified data from over 10 health systems
Learn how to enroll your program, contribute data, and be part of a peer-reviewed publication on the economic benefits of these programs
Plan to leave with actionable steps to participate in the VALUE Study

Speakers:

Feyi Ayodele, CEO, CancerIQ
Dr. Jeff Weitzel, Director, Division of Precision Prevention, University of Kansas Cancer Center
Brittany Thomas, Senior Manager, Research and Scientific Communications, CancerIQ